ODAC 30% Off Registration, Use Code: JDD30
Skip to main content
Featured ArticlesGlobal Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

By March 30, 2020April 29th, 2020No Comments

Dermatology News

Featured Article

Dermatologist looking at skin

"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”

As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.

Read Full Article Now

You May Also Like

Featured ArticlesThe LatestVideo AbstractNew Video Abstract: Fundamentals of Hyperpigmentation Disorders: Causes, Concerns, and Treatment Strategies Particularly in Skin of Color Patients with Dr. Susan Taylor!
October 30, 2026

New Video Abstract: Fundamentals of Hyperpigmentation Disorders: Causes, Concerns, and Treatment Strategies Particularly in Skin of Color Patients with Dr. Susan Taylor!

Pigmentary disorders, including cutaneous hyperpigmentation, are among the most common dermatologic diagnoses in individuals with SOC, particularly individuals with African, Asian, or Hispanic heritage. The principal hyperpigmentation conditions include melasma, post-inflammatory…
Journal of Drugs in Dermatology JDD featuring SAIGE III: The Role of Environmental Factors in the Development and Severity of Atopic Dermatitis in Young ChildrenAtopic DermatitisFeatured ArticlesLatest NewsPediatricsSAIGE III: The Role of Environmental Factors in the Development and Severity of Atopic Dermatitis in Young Children
October 29, 2026

SAIGE III: The Role of Environmental Factors in the Development and Severity of Atopic Dermatitis in Young Children

Protecting the Pediatric Skin Barrier: Expert Consensus on Environmental Triggers and Early Intervention This is a must-read article from JDD for clinicians  managing pediatric skin health. Atopic dermatitis frequently begins in…
Journal of Drugs in Dermatology JDD featuring Beyond the Dark Spot: Modern Strategies for Stubborn HyperpigmentationDyspigmentationFeatured ArticlesLatest NewsPhotoprotectionBeyond the Dark Spot: Modern Strategies for Stubborn Hyperpigmentation
October 28, 2026

Beyond the Dark Spot: Modern Strategies for Stubborn Hyperpigmentation

From iron oxides to depigmenting agents, how new research is changing tone correction Unlocking clear skin is a constant goal for patients, which is why hyperpigmentation research routinely tops JDD…

Leave a Reply